4 results
To investigate what the ideal moment to vaccinate would be, early (after 2-6 months) or late (after 9-12 months) after cessation of rituximab. Secondly to study the immune-response to vaccination with influenza virus vaccine after treatment with…
1. To decipher the biological basis underlying the alterations in ubiquitination of histones in response to anthracyclines and proteasome inhibitors.2. to find out whether the combined use of anthracyclines and proteasome inhibitors has additive or…
Objective: Our main objective is to assess in detail risk factors for cardiovascular disease and cardiotoxicity and to compare heart function parameters, vascular parameters and biomarkers associated with cardiovascular function among 5- to 18-year…
This study has been transitioned to CTIS with ID 2023-504805-35-00 check the CTIS register for the current data. Dose Escalation PhasePrimary - Evaluate the safety and tolerability of epcoritamab in combination with other agents Secondary-…